摘要
目的:免疫检查点在包括人肺腺癌(lung adenocarcinoma,LUAD)的免疫治疗中取得了突破性进展,而HHLA2(Human endogenous retrovirus-H long terminal repeat-associating protein 2,人内源性逆转录病毒H长末端重复结合蛋白2)是最近发现的免疫调节分子B7同源家族的成员。本文研究HHLA2在LUAD中的表达情况和临床意义。方法:采用免疫组化方法检测74例LUAD患者及相应的癌旁组织中HHLA2的表达情况。结果:与癌旁组织相比, HHLA2在LUAD的肿瘤组织中显著过表达(P<0.05),但并未发现与其他临床病理参数的相关性。结论:HHLA2与肺腺癌的发生有关,是潜在的免疫治疗靶点。
Objective:Immune checkpoints has made a breakthrough in cancer treatment including human lung adenocarcinoma(LUAD),whereas HHLA2(Human endogenous retrovirus-H long terminal repeat-associating protein 2)is the recently identified member of the B7 homologue family of immune-regulatory molecules.This study was designed to investigate the expression patterns and clinical significance of HHLA2 in LUAD tissues.Methods:Immunohistochemistry method was performed to examine the expression of 74 patients of LUAD and adjacent tissues in HHLA2.Results:Compared with adjacent tissues,HHLA2 were significantly overexpressed in the tumor tissues of LUAD(P<0.05);However,no significant correlation was observed between HHLA protein and other clinical features of LUAD patients.Conclusion:HHLA2 is correlated with the development of LUAD,it is a potential immunotherapeutic target.
作者
南方圆
陈梦茜
陈洪雷
Nan Fangyuan;Chen Mengxi;Chen Honglei(Department of Pathology,Basic Medical College of Wuhan University,Wuhan 430000;Department of Thoracic Surgery,Wuhan Jiangxia People's Hospital,Wuhan 430000)
出处
《数理医药学杂志》
2019年第10期1426-1428,共3页
Journal of Mathematical Medicine
